<DOC>
	<DOCNO>NCT00002984</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus radiation therapy treat patient advanced metastatic cancer esophagus .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Advanced Metastatic Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Define maximum tolerate dose ( MTD ) paclitaxel ( TAX ) give 3 hour infusion combination cisplatin ( CDDP ) , fluorouracil ( 5-FU ) , radiation therapy . II . Define toxicity profile TAX give 3 hour infusion combination CDDP , 5-FU , radiation therapy . III . Evaluate effectiveness TAX contain chemotherapy regimen concurrent radiotherapy follow resection treatment locally advanced esophageal cancer judge complete response rate , pathological complete response rate , time recurrence , overall survival . OUTLINE : Patients receive radiation tumor nodal area 5 day week 5 week . Patients receive chemotherapy consist cisplatin ( CDDP ) via rapid intravenous infusion day 1 follow fluorouracil ( 5-FU ) via 96-hour continuous infusion ( CI ) day 1 4 ; repeat last 4 day radiation therapy ( day 29-31 ) , additional dose CDDP day 29 96-hour CI 5-FU day 29-31 . Patients also receive paclitaxel ( TAX ) weekly 3 hour infusion day 1 , 8 , 15 , 29 , 3 patient treat dose level subsequent patient treat accord toxicity observe previous cohort . TAX give prior CDDP 5-FU week give concurrently . The MTD TAX define dose 1 6 patient experience dose-limiting toxicity . Surgical resection take place 2-8 week follow completion chemoradiotherapy patient except disease progression surgically unresectable medically unfit ( include metastatic disease ) tolerate surgery . An additional course TAX/CDDP/5-FU give 28-35 day surgery . PROJECTED ACCRUAL : Three patient enter low dose level TAX , 3-6 patient enter three additional dose level TAX phase I study . An additional group 11 patient accrue first stage modify phase II study 38 second stage , warrant . The study complete within 3-4 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose locally advanced adenocarcinoma squamous cell carcinoma esophagus Evidence disease extension wall esophagus ( T2 T4 ) and/or regional nodal metastasis ( N1 ) Patients distant metastatic disease undergo resection may also treat phase I portion trial eligible modify phase II portion Patients enter modified phase II portion trial must evaluable ( measurable one dimension ) measurable disease primary site PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 2 month metastatic disease 2 year locally advance disease Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dl Renal : Creatinine clearance least 60 mL/min Serum creatinine great 1.5 mg/dL Cardiovascular : No history refractory congestive heart failure cardiomyopathy Other : Not pregnant No malignancy within 5 year except : Curatively treat carcinoma situ cervix Basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : More 1 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>